Background COVID-19 is characterized by a heterogeneous clinical presentation, ranging
from mild symptoms to severe courses of disease. 9–20% of hospitalized patients with …

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is characterized by respiratory distress, multiorgan …

Pulmonary fibrosis is a sequelae of Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) infection that currently lacks effective preventative or therapeutic measures …

The novel SARS-CoV-2 coronavirus, which is responsible for COVID-19 disease, was first
reported in Wuhan, China, in December of 2019. The virus rapidly spread, and the World …

The development of lung fibrosis is a major concern in patients recovered from severe
COVID-19 pneumonia. This study aimed to document the evolution of diffuse alveolar …

Background Progressive respiratory failure is the primary cause of death in the coronavirus
disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of …

Pulmonary fibrosis is a devastating disease, and the pathogenesis of this disease is not
completely clear. Here, the medical records of 85 Covid-19 cases were collected, among …

Pulmonary fibrosis (PF) is a feared outcome of many pulmonary diseases which results in a
reduction in lung compliance and capacity. The development of PF is relatively rare, but it …

Despite intensive studies during the last 3 years, the pathology and underlying molecular
mechanism of coronavirus disease 2019 (COVID‐19) remain poorly defined. In this study …

Abstract Background Coronavirus disease 2019 (COVID-19) patients can develop
pulmonary fibrosis (PF), which is associated with impaired outcome. We assessed specific …